Diponegoro University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Semarang Indonesia (1957)

Organization Overview

First Clinical Trial
2012
NCT01645332
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Diponegoro University | Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia | Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital, Semarang, Indonesia | Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia. | Dr. Kariadi General Hospital | Faculty of Medicine, Diponegoro University, Semarang | Faculty of Medicine Universitas Diponegoro | Faculty of Medicine University of Diponegoro, Indonesia | Kariadi Hospital | Neurology Department Dr. Kariadi General Hospital | Universitas Diponegoro

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Gastroesophageal Reflux (Phase 3)

Hepatitis (Phase 3)

Hepatitis B (Phase 3)

Infarction (Phase 3)

Insulin Resistance (Phase 3)

Ischemia (Phase 3)

Polycystic Ovary Syndrome (Phase 3)

Psychomotor Agitation (Phase 4)

Stroke (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 19